Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Perfect day. Momo keep on trucking!
Any idea when we might hear back from AMEX regarding CRMD’s plan to bring itself back into compliance?
You’d have to have seen 200 of the 5.000 transactions to hit a mil. I’ll check later. Good luck to you.
5000 or 50000?
When I get home tonight I’ll pull today’s buy and sell transactions from E*TRADE and let ya know.
Just saw volume only 1.3M so I doubt it.
How can that be verified?
Yeah, that strike price is a little higher than I am comfortable with as well, but let’s unbind those results, baby.
Got it; and thank you both. I hope I didn’t jump the gun with March. My only concern is pulling the trigger prematurely. Hopefully 218 days is long enough to get it sorted.
If not, well, it won’t be the first time I’ve been wrong timing a biotech. :-0
Lazer, I am the proud papa of gobs of March 19 call options and a few (70) for December. Both are $2.50 strike price.
Given the recent turn of events, including today’s filing (which I believe we’re going to see more of), I’m on the fence about reloading on March, or holding off for to see when news dates are introduced. Generally speaking, are there specific dates the markets will add new option opportunities?
Sorry, it may actually be NASR and NSDQ. Forgot which FRICK and FRACK combo it is.
ARCA and AMEX are back on the Ask Swallowing up shares.
Looks like CRMD tapping ATM again. I thought they had enough loot through Q4?
Frustrating.
Thanks for sharing your thoughts with respect to the call.
The one stick of TNT that makes me a little nervous is if the FDA tells them to run the 2nd Phase 3 trial. But to your point, they seem confident so let's hope that's now, well, just hope.
Two other interesting items:
1. We will consider opportunistic financing earlier to ensure sufficient funds for our planned operations. Yes, we believe such a transaction would be in our shareholders best interest. We will provide an update on our CRO negotiations as soon as possible.
To me, that sounds like "hey, Daddy Warbucks, text me".
2. Yes, we do have a draft plan of what a commercial organization would look like, but I also fully understand the challenges and risk for a small company faces to build a commercial market access infrastructure here in the U.S., particularly when you only have one product in the bag. Therefore, in parallel, we will be very open and in some cases be very proactive in identifying strategic partnerships, as long as it’s in the best interest of our shareholders.
Very proactive makes me smile, provided, it's in the best interest of the shareholders.
Personally, Khoso said it best: it's a 17 person outfit. Reading between the lines, as I always do, after all this time, if they are in a position to punch out with a sweet deal, I believe they will.
Going from developmental to commercial is a huge undertaking, IMO. If they can gain immediate benefit for all their hard work, why not? That's what I would do, anyway.
Good luck to all!
They are waaay too confident!
They know they have Secretariat in the stable.
Next court date is November.
Or we prevail in court against TauroPharm, who’ve essentially undercut them using a variation of CRMD’s technology.
Sorry if this is rehash, but it’s a pretty good article I thought I’d share.
http://www.streetwisereports.com/article/2018/07/31/interim-readout-for-pharma-trial-delivers-home-run.html
I appreciate your opinion. Thank you for the response. I think you are spot on with respect to trying to predict what ultimately will happen.
The folks in charge back then are not calling the shots now, so trying to base future events based on past moves is a quick way to lose coin.
In the end, the play is the long game.
Glad we’re in.
Have a nice weekend.
Good point about FDA approval first. Do I understand correctly that the FDA will respond with 60 days of NDA submission?
And finally, do you know if a dollar value been determined with respect to damages against TauroPharm, re: Prosl patent. In particular, damages for sales for their TauroLock-HEP product line? Before I burn time looking I thought I’d see if you had some knowledge to share.
From CRMD’s filings, it’s clear it’s anything but a lock, but sometimes a company does get a couple of good bounces it’s way.
Thanks again and have a good weekend!
Lazer, what’s the over/under on Tuesday CRMD announcing that it’s going the 2015 route and bringing in another Evercore for possible buyout?
Locked and loaded. 37K shares. To the moon!!!
Boom! I can’t wait for earnings!
Twice he made clear to say MORE THAN 3M.
Our time is coming.
Laughable. Triton is a marketing gimmick. A couple of snot-nosed kids used to soften negotiations engineered by their backers:think Daniel Planview in There Will Be Blood.
Tell ‘em to take their $275K - $2M investment and piss off.
WELL OVER 3M Subscribers.
I’m not.
Thanks Clay TraderTron!
FTI, your magic 8 ball doesn’t count as a verifiable source.
You really are looking to get schooled. "Watch and Learn" BWAHAHAHAH
I'll park my cash the same place Morgan Stanley does over an internet poster trying to school iHub about HMNY. ROFLMAO!
What would your estimate range fall under?
Gotcha. Thanks
6-9 months is what he indicated yesterday.
I’ll be diving in for more late Friday or Monday. Even if I miss a $.15 swing during that time I fear nothing as this pocket rocket is going to make long term holders proud this year.
GIDDY UP.
Damn Bob, very well thought out. Thank you for the time you spent on this, and thank you for sharing with us.
Perpetual dark cloud. LoL.
Twice he made clear the sub numbers are well above 3M. Depending on just how much above makes all the difference. At a minimum, it should absorb and mitigate anticipated negative rev numbers.
If they can show gains, however small, in monetizing customer data, it presents a model of sustainability.
And for $.07, where can you find a better ROI, IMO.
WELL OVER 3 million subscribers. Are each paying 9.99 a month?!?!?!
At 3.5M subscribers, that’s $105M per Q, annualized $420M?
I must be doing the math wrong.
HMNY averaging more than 1 institutional investor buying per day since 1 August. 9 in 8 days (per Fintel).
Why?
Stock reduced to rubble in a month and the cool kids know there’s plenty of meat on the bones.
Earnings, please post on Friday.
BOOM.